Regen BioPharma Inc (RGBP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Regen BioPharma Inc (RGBP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH408581D
  • |
  • Pages: 49
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Regen BioPharma Inc (Regen BioPharma), a subsidiary of Bio-Matrix Scientific Group Inc is a biotechnology company that concentrates on the development of immunotherapies and cancer stem cell therapies. The company's product pipeline includes HemaXellerate, dCellVax, DiffronC, small molecule targeting cancer stem cell genes, telomeres and genomic integrity. It provides products for aplastic anemia, myelodysplastic syndrome, solid tumors and acute leukemia, breast cancer, hematopoiesis and liver cancer, among others. The company spans its expertise in the development of therapies including small molecules, stem cell treatments and the body's own immune system. Regen BioPharma is headquartered in La Mesa, California, the US.

Regen BioPharma Inc (RGBP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Regen BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Regen BioPharma Inc, Medical Devices Deals, 2011 to YTD 2017 10

Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Regen BioPharma Acquires Labs Facilities in US 13

Regen BioPharma Acquires Issued Patent and Preclinical Data Package for Targeting Cancer Stem Cell 14

Regen BioPharma to Acquire Cancer Stem Cell Intellectual Property from University of Toronto 15

Regen BioPharma Completes Acquisition Of Patented Intellectual Property Of Cancer Gene-Silencing Technology 16

Venture Financing 17

Regen BioPharma Raises USD20 Million In Venture Financing 17

Partnerships 18

Regen BioPharma Enters into Agreement with ChemDiv 18

Regen BioPharma to Enter into Agreement with Eli Lilly 19

Regen BioPharma Enters into Research Agreement with National Institutes of Health 20

Licensing Agreements 21

CheckPoint Immunology Enters into Licensing Agreement with Regen BioPharma 21

Regen BioPharma Enters Licensing Agreement with Pan Am Cancer Treatment Center 22

Benitec Biopharma Enters Into Licensing Agreement With Regen BioPharma For ddRNAi Gene Silencing Technology 23

Equity Offering 24

Regen BioPharma Raises USD0.05 Million in Private Placement of Units 24

Regen BioPharma Raises USD0.05 Million in Private Placement of Units 25

Regen BioPharma Raises Funds in Private Placement of Units 26

Regen BioPharma Raises USD0.15 Million in Private Placement of Units 27

Regen BioPharma Raises USD0.1 Million in Private Placement of Shares 28

Regen BioPharma Raises USD0.1 Million in Private Placement of Shares 29

Regen BioPharma Raises USD0.1 Million in Private Placement of Shares 30

Regen BioPharma Raises USD0.1 Million in Private Placement of Shares 31

Debt Offering 32

Regen BioPharma Raises Funds in Public Offering of 10% Notes Due 2020 32

Regen BioPharma Raises Funds in Public Offering of 10% Notes Due 2020 33

Regen BioPharma Raises Funds in Public Offering of 10% Notes Due 2020 34

Regen BioPharma Raises Funds in Public Offering of 10% Notes Due 2020 35

Regen BioPharma Inc-Key Competitors 36

Regen BioPharma Inc-Key Employees 37

Regen BioPharma Inc-Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Recent Developments 39

Corporate Communications 39

Jun 01, 2016: Regen BioPharma Uplisted to Trade Publicly on OTCQB 39

May 24, 2016: Regen BioPharma Files Application to Trade Publicly on OTCQB 40

Product News 41

Sep 20, 2016: Regen BioPharma Receives Positive Data From Preclinical Studies of Its Small Molecule NR2F6 Modulators 41

Jul 12, 2017: Regen BioPharma Researchers Discover New Dynamic Compound Which Modulates the NR2F6 Checkpoint 42

May 16, 2017: Regen BioPharma Sees Additional Positive Results on its Medicinal Chemistry Optimization for Modulating NR2F6 Checkpoint for Treating Cancer and Autoimmune Diseases 43

Apr 18, 2017: Regen BioPharma Identifies Three New Series of Compounds That Activate NR2F6 44

Apr 12, 2017: Regen BioPharma Sees Success in Its Pre-Clinical Small Molecule Optimization Program for NR2F6 45

Mar 23, 2017: Regen BioPharma Provides Update on NR2F6 Small Molecule Optimization Program for Treating Cancer and Arthritis 46

Other Significant Developments 47

Jul 13, 2016: Regen BioPharma President Harry Lander Provides Mid-year Update on Company's Progress and Developments 47

Appendix 49

Methodology 49

About GlobalData 49

Contact Us 49

Disclaimer 49

List of Figures

Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2

Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2

Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2

Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2

Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Regen BioPharma Inc, Medical Devices Deals, 2011 to YTD 2017 10

List of Tables

Regen BioPharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2

Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Regen BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Regen BioPharma Inc, Deals By Therapy Area, 2011 to YTD 2017 9

Regen BioPharma Inc, Medical Devices Deals, 2011 to YTD 2017 10

Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Regen BioPharma Acquires Labs Facilities in US 13

Regen BioPharma Acquires Issued Patent and Preclinical Data Package for Targeting Cancer Stem Cell 14

Regen BioPharma to Acquire Cancer Stem Cell Intellectual Property from University of Toronto 15

Regen BioPharma Completes Acquisition Of Patented Intellectual Property Of Cancer Gene-Silencing Technology 16

Regen BioPharma Raises USD20 Million In Venture Financing 17

Regen BioPharma Enters into Agreement with ChemDiv 18

Regen BioPharma to Enter into Agreement with Eli Lilly 19

Regen BioPharma Enters into Research Agreement with National Institutes of Health 20

CheckPoint Immunology Enters into Licensing Agreement with Regen BioPharma 21

Regen BioPharma Enters Licensing Agreement with Pan Am Cancer Treatment Center 22

Benitec Biopharma Enters Into Licensing Agreement With Regen BioPharma For ddRNAi Gene Silencing Technology 23

Regen BioPharma Raises USD0.05 Million in Private Placement of Units 24

Regen BioPharma Raises USD0.05 Million in Private Placement of Units 25

Regen BioPharma Raises Funds in Private Placement of Units 26

Regen BioPharma Raises USD0.15 Million in Private Placement of Units 27

Regen BioPharma Raises USD0.1 Million in Private Placement of Shares 28

Regen BioPharma Raises USD0.1 Million in Private Placement of Shares 29

Regen BioPharma Raises USD0.1 Million in Private Placement of Shares 30

Regen BioPharma Raises USD0.1 Million in Private Placement of Shares 31

Regen BioPharma Raises Funds in Public Offering of 10% Notes Due 2020 32

Regen BioPharma Raises Funds in Public Offering of 10% Notes Due 2020 33

Regen BioPharma Raises Funds in Public Offering of 10% Notes Due 2020 34

Regen BioPharma Raises Funds in Public Offering of 10% Notes Due 2020 35

Regen BioPharma Inc, Key Competitors 36

Regen BioPharma Inc, Key Employees 37

Regen BioPharma Inc, Subsidiaries 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Regen BioPharma Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16088
Site License
USD 500 INR 32175
Corporate User License
USD 750 INR 48263

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com